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1. INTRODUCTION
1.1 Controlled drug delivery- The controlled drug 
delivery systems have been introduced to overwhelm the 
drawback of fluctuating drug levels associated with 
conventional dosage forms. The concept of sustained or 
prolonged release of biologically active agents has been 
well appreciated and randomized for decades. Basically 
there are three basic modes of drug delivery, i.e. targeted 
delivery, controlled release and modulated release. 
Controlled release refers to the use of a delivery device 
with the objective of releasing the drug into the patient 
body at a predetermined rate, or at specific times or with 
specific release profiles 1. 
1.1.1 Background of controlled drug delivery - lipid 
nanoemulsions were introduced during the 50’s for the 
purpose of parenteral nutrition where 10-20% of total 
amount of fatty vegetable oils (e.g. soy oil) or middle chain 
triglycerides in emulsion as a lipid content were used and 
other ingredients were Phospholipids (stabilizer-0.6-1.5 %) 
and glycerol (osmorality-regulation, 2.25%) were added. 
During recent years more lipophilic formulations were 
commercialized e.g. etomidate (Etomidat-Lipuro®) and 
Diazepam (Diazepam-Lipuro®) 2,3. In the beginning of 80’s, 
Speiser and coworkers developed solid lipid nanoparticles 
(by spray drying) and Nanopellets for peroral 
administration. The nanopellets developed by speiser were 
formulated by mixing melted lipids with high shear 
homogenizer but it was indicated that it was producing high 
quantity of microparticles as compared to nanoparticles. 
Then high pressure homogenization was developed, with 
this the 500 nm sized and low microparticles sized particles 
were characterized. 4  
1.1.2 Examples of colloidal particles are as follows:
1.1.2.1 Dendrimers- Dendrimers are branched 
macromolecules in which each level of branching is 
classified as a generation. Generally, dendrimeric polymers 
developed for drug delivery have a multifunctional 
hydrophobic inner core that is conjugated to outer 
hydrophilic moieties, such as PEG. Dendrimeric polymers 
are promising drug delivery materials because they possess 
narrow polydispersity and can be designed with many 
combinations of size, shape, and surface chemistry. 5
1.1.2.2 Liposomes- liposomes are aqueous compartments 
enclosed in lipid bilayer membranes and consist of layered 
lattices of alternating bimolecular sheets of lipids such as 
phosphatidylcholine, carebrosides, cholesterol etc. They 
may be unilayered or multilayered and are known as 
unilamellar or multilamellar liposomes. 5
1.1.2.3 Nanoemulsion- For a nanoemulsion formulation 
to include stable particles of a desired size, the interactions 
between the core- and shell- forming materials often 
require optimization. This can be done by experimentally 
by selecting compatible components and determining the 
appropriate mixing ratio. 5
1.1.2.4 Micelles formed from linear block copolymer-
Linear, amphiphilic diblock triblock co-polymers have 
emerged as the materials of choice for use in a wide range 
of biomedical applications, including fabrication or coating 
of biomedical devices, drug delivery, and tissue 
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engineering. Polymeric micelles comprise a hydrophobic 
core, which can load and store drugs as cargo, and a 
hydrophilic shell, which surrounds and solubilizes the 
hydrophobic core and hinders interactions with components 
of the host mononuclear phagocytic system. 5
1.1.2.5 Micelles formed from star-shaped block co-
polymers- Unimolecular micelles are inherently stable to 
dilution and may be prepared to be monodisperse and of a 
smaller size than most multimolecular systems. Star shaped 
block co-polymers are an excellent material for making 
unimolecular micelles, provided the molecules can be 
engineered to avoid self aggregation 5
1.1.2.6 Solid lipid Nanoparticles- Solid lipid 
nanoparticles are the nano-carriers which remain solid at 
room temperature and changes into liquid form while 
melting at increasing temperature. SLN are composed of 
0.1% (w/w) to 30% (w/w) solid lipid dispersed in an 
aqueous medium and if necessary stabilized with preferably 
0.5% (w/w) to 5% (w/w) surfactant. The incorporation of 
cosmetic and pharmaceutical actives is feasible. The mean 
particle size of SLN is in the submicron rage, ranging from 
about 40 to 1000nm. In the second generation of the lipid 
nanoparticle technology, the particles are produced using 
blends of solid lipids and liquid lipids (oils). To obtain the 
blends for the particles matrix, solid lipids are mixed with 
liquid lipids (oils), preferably in a ratio of 70:30 upto a ratio 
of 99.9:0.1. The major advantage of SLN is the possibility 
of production on large industrial scale. However, 
depending on the drug some potential problems can occur, 
such as drug leakage during storage and insufficient total 
drug load. To overcome the limitations of SLN, 
nanostructured lipid carriers (NLC) have been developed. 
The later consists of a solid lipid matrix with a high content 
of liquid lipid.6
Figure 1.2.1: Formation of an almost perfect crystalline structure in SLN (left) by identically shaped molecules similar to a 
brick wall with limited loading capacity for actives. Formation of a solid particle matrix of NLC (right) with many 
imperfections comparable to building a wall from very differently shaped stones, the increased number of imperfections 
leads to an increased loading capacity for active compounds. 
Table 1.2.1: Lipids and emulsifiers used for preparation of solid lipid nanoparticles [4]
Lipids Emulsifiers/Coemulsifiers
Triglycerides Soybean lecithin
Tricaprin (LipoidÒ S 75, LipoidÒ S 100)
Trilaurin Egg lecithin (LipoidÒ E 80)
Trimyristin Phosphatidylcholine
Tripalmitin (EpikuronÒ 170, Epikuron 200)
Tristearin Poloxamer 188
Hydrogenated coco-glycerides Poloxamer 182
(SoftisanÒ ) Poloxamer 407
Hard fat types Poloxamine 908
WitepsolÒ W 32 Tyloxapol
WitepsolÒ H 35 Polysorbate 20
WitepsolÒ H 42 Polysorbate 60
WitepsolÒ E 85 Polysorbate 80
Glyceryl monostearate (ImwitorÒ900) Sodium cholate
Glyceryl behenate (CompritolÒ 888 ATO) Sodium glycocholate
Glyceryl palmitostearate (PrecirolÒ ATO 5) Taurocholic acid sodium salt
Cetyl palmitate Taurodeoxycholic acid sodium salt
Stearic acid Butanol
Palmitic acid Butyric acid
Decanoic acid Dioctyl sodium sulfosuccinate
Behenic acid Monooctylphosphoric acid sodium
Acidan N12
In Fig. 1.2.2, the REM of Compritol stabilized with poloxamer 188 is showing the size and shape of the typical solid lipid 
nanoparticle structure. The table 1.2.1 and 1.2.2 showing the types and properties like melting points, % of glycerides and 
hydroxyl value.
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Figure 1.2.2: Picture of solid lipid nanoparticles made from Compritol stabilized with Poloxamer 188, diameter 400 nm.
Table 1.2.2: Chemical composition, melting point and hydroxyl value of lipids used as SLN matrix 8
Lipid % of glycerides Melting Point Hydroxyl value
Mono- Di- Tri- (0C) (mg KOH/g)
Dynasan 112 - 3 96 43-47 Max. 10
Dynasan 114 - 4 95 55-58 Max. 10
Dynasan 116 - 3 96 61-65 Max. 10
Dynasan 118 - 2 97 70-73 Max. 10
Softisan 138 - 11 88 37-40 Max. 15
Softisan 142 - 10 89 42-44 Max. 15
Softisan 154 - 3 96 53-58 Max. 10
Compritol 888 13-18 52-54 28-32 ~70 80-105
Imwitor 900 40-50 ~40 ~5 56-61 300-330
Precirol Ato 5 8.-17 ~54 ~30 52-55 90-110
Witepsol S 51 4 33 62 30-32 55-70
Witepsol S 55 10 14 75 33.5-35.5 50-65
1.1.3The main factors related with SLN administration:
1.2.6.1.1 Method of preparation influences structures of 
SLN-The drug enriched shell and drug enriched core are of 
two types of crystallization structures. The former is 
obtained while repartitioning of the drug while cooling. 
And the drug enriched core will be found in case the drug 
precipitates first before the lipid recrystallizes. It is 
obtained when dissolving a drug (e.g. Prednisolone) in the 
lipid melt at or close to its saturation solubility. Cooling of 
the nanoemulsion will lead to a super saturation of drug in 
the melted lipid and subsequently to the drug crystallization 
prior to the lipid crystallization.
1.2.6.1.2 Degree of Crystallization- The polymorphic 
form is also a parameter to determine the drug 
incorporation. At storage the lipid particles can change 
from amorphous to crystalline state after recrystallization. 
Where the main factors to transformation are temperature 
and water loss in the SLN nanodispersion. 
1.2.6.1.3 Adhesiveness- It is a general property of the very 
fine particles that means nanoparticles of different kinds. 
Such a lipid film formation will be able to restore a 
damaged protective lipid film on the skin. Such a film can 
have occlusive effect.
1.2.6.1.4 Occlusive effect-The occlusive effect of the SLN 
membrane was evaluated by using Cream base, SLN-
containing cream base and gel formulation were incubate at 
24 hours. where TEWL (Transepidermal water loss) was 
determined for each as the moisture content in the SLN was 
present. It has shown that, 33 % was moisture present in the 
skin area as compared to the 23% of formulation having 
SLN-Free base. 7
1.2.6.2 
1.2.6.2.1 Advantages of SLN & NLC-
a. These carriers are composed of physiological and 
biodegradable lipids of low systemic toxicity and also low 
cytotoxicity. Most of the used lipids have an approved 
status or are excipients used in commercially available 
topical cosmetic or pharmaceutical preparations. 
b. The small size of the lipid particles ensures close contact 
to the stratum corneum and can increase the amount of the 
drug penetrating into the mucosa or skin.
c. Due to their lipid matrix, controlled release from these 
carriers is possible.
1.2.6.2.2 Disadvantages of SLN & NLC-
a. Lipid crystallization modifications- The crystalline state 
of the molecule will change into amorphous state while 
storage. So that the drug expulsion could be takes place in 
the Solid lipid nanoparticles. But it could be overcome by 
adding liquid chemical penetration enhancer in the solid 
lipid can enhance the drug loading and prevents the drug 
expulsion due to defects occurred in the structure of carrier 
from crystalline to the amorphous state.
b. Difficult to scale up- The probe does not reach to every 
corner of the container having Emulsion used to reduce 
particles into nano-sized at the large scale production.
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c. Cost effective-The homogenizer is expensive than 
instruments used to formulate conventional drug 
formulations.
d. Particles aggregation could be possible- The 
aggregation of the particles could be take place because of 
the nano-sized. 7
1.2.6.3 Methods of Preparation of SLN
1.2.6.3.1 High Pressure homogenization
a. Cold Homogenization method
b. Hot Homogenization method
Lipid nanoparticles can be produced by either the hot or 
cold high pressure homogenization technique. Fig. 1.3 
shows schematically the steps of these two methods. The 
active compound is dissolved or dispersed in melted solid 
lipid for SLN or in a mixture of liquid lipid (oil) and melted 
solid lipid for NLC. In the hot homogenization method the 
lipid melt containing the active compound is dispersed in a 
hot surfactant solution of the same temperature (5–10 ◦C 
above the melting point of the solid lipid or lipid blend) by 
high speed stirring. The obtained emulsion (generally 
called pre-emulsion) is then passed through a high pressure 
homogenizer adjusted to the same temperature generally 
applying three cycles at 500 bar or two cycles at 800 bars. 
In the cold homogenization method, the active containing 
lipid melt is cooled down. After solidification the mass is 
crushed and ground to obtain lipid microparticles. The lipid 
microparticles are then dispersed in a cold surfactant 
solution yielding a cold pre-suspension of micronized lipid 
particles. This suspension is passed through a high pressure 
homogenizer at room temperature applying typically 5–10 
cycles at 1500 bar. Addition of SLN or NLC to an existing 
product, e.g. cream or lotion, is realized by replacing a part 
of the water phase with concentrated SLN or NLC 
dispersion. To maintain the lipid content of the original 
cream or lotion, the lipid content of the original formulation 
can be reduced about the amount of incorporated lipid from 
the lipid nanoparticles. The creams and lotions are 
produced using the established way of production, cooled 
to about 30 ◦C, and the concentrated lipid nanoparticles 
suspension is then admixed applying gentle stirring. 
Instabilities of lipid nanoparticles in cosmetic or 
pharmaceutical creams or lotions containing oil droplets 
that might occur are
aggregation or dissolution. The presence of solid lipid in 
such formulations can be proven by differential scanning 
calorimetry (DSC). The particle size can be determined 
using photon correlation spectroscopy (PCS) or laser 
diffractometry (LD). Hydrogel formulations (xanthan gum, 
hydroxyethylcellulose 4000, Carbopol 943 and chitosan) 
containing SLN or NLC were investigated regarding the 
physical stability of the lipid nanoparticles. For both lipid 
nanocarriers a good physical stability was reported. Using 
high lipid concentrations a final product can be produced in 
one step. These particle dispersions have a relatively high 
consistency; they are cream like or almost solid. By PCS, 
LD and electron microscopy the existence of intact 
particles can be proven. 6 In the un-published results of 
experiment with insoluble drug, the 4 microns sized 
particles are obtained but was non-uniform sized.
Fig 1.3: Production process of lipid nanoparticles using cold (light gray background) and hot (dark gray 
background) high pressure homogenization technique 6
1.2.6.3.2 Solvent-diffusion evaporation method- In this 
method, the drug and lipid dissolves in organic solvent and 
put this solution drop wise in the surfactant solution. After 
stirring, the solution is transferred in the High pressure 
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homogenization. The solvent evaporation by Rota-
evaporator would be the last step in the SLN Formation. 
Sjostrom and Bergenstahl described a production method to 
prepare nanoparticle dispersions by pre-cipitation in o/w 
emulsions. The lipophilic material is dissolved in a water-
immiscible organic solvent (e.g. cyclohexane) that is 
emulsified in an aqueous phase. Upon evaporation of the 
solvent nanoparticle dispersion is formed by precipitation 
of the lipid in the aqueous medium. 4
1.2.6.3.3 Ultrasonication method- It is also named as high 
speed homogenization method. High shear homogenization 
and ultrasound are dispersing techniques which were 
initially used for the production of solid lipid 
nanodispersions . Both methods are widespread and easy to 
handle. However, dispersion quality is often compromised 
and by the presence of microparticles. Furthermore, metal 
contamination has to be considered if ultra-sound is used. 
Ahlin et al. used a Lak Tek rotor–stator homogenizer 
(Omni International, Gainesville, USA) to produce SLN by 
melt–emulsification. They investigated the influence of 
different process parameters, including emulsification time,
stirring rate and cooling conditions on the particle size and 
the zeta potential. Lipids used in this study include 
trimyristin (DynasanÒ114), tripalmitin Hot 
(DynasanÒ116), tristearin (DynasanÒ118), a mixture of 
mono-, di- and triglycerides (WitepsolÒW35, 
WitepsolÒH35) and glycerol behenate  (CompritolÒ888 
ATO), poloxamer 188 was used as steric stabilizer (0.5 
w%). 4
1.2.6.3.4 Membrane contactor- In this method, the lipid 
phase is pressed, at a temperature above the melting point 
of the lipid, through the membrane pores allowing the 
formation of small droplets. The aqueous phase circulates 
inside the membrane module, and sweeps away the droplets 
forming at the pore outlets. SLN are formed by the cooling 
of the preparation at room temperature. The influence of 
the process parameters (aqueous phase and lipid phase 
temperatures, aqueous phase cross-flow velocity and lipid 
phase pressure, membrane pore size) on the SLN sire and 
on the lipid phase flux was investigated. The 70 and 215 
nm sized particles were formulated. 9
a. Advantages of the membrane contactor method-
Uniform Sized particles could be obtained as per the pore 
size.
Mechanical handling of the nanoparticles could be 
obtained.
No aggregation could take place.
b. Disadvantages of membrane contactor method-
Scalability
Expensive
1.2.6.4 Influences of the Ingredient Composition in the 
Product Quality of SLN:
1.2.6.4.1 Influence of the emulsifier in SLN 
Formulation- High concentrations of the emulsifier reduce 
the surface tension and facilitate the particle partition used 
during homogenization. The decrease in particle size is 
connected with a tremendous increase in surface. The 
increase of the surface area during HPH occurs very 
rapidly. Therefore, kinetic aspects have to be considered. 
The process of a primary coverage of the new surfaces 
competes with the agglomeration of uncovered lipid 
surfaces. The primary dispersion must contain excessive 
emulsifier molecules, which should rapidly cover the new 
surfaces.
1.2.6.4.2 Influence of the lipids concentration in SLN 
Formulation- Using the hot homogenization, it has been 
found that the average particle size of SLN dispersions is 
increasing with higher melting lipids. These are in 
agreement to the general theory of HPH and can be 
explained by the higher viscosity of the dispersed phase. 
However, other critical parameters for nanoparticle 
formation will be different for the different lipids. 
Examples include the velocity of lipid crystallization, the 
lipid hydrophilicity (influence on self-emulsifying 
properties) and the shape of the lipid crystals (and therefore 
the surface area). It is also noteworthy, that most of the 
lipids used represent a mixture of several chemical com 
pounds. The composition might therefore vary from 
different suppliers and might even vary for different 
batches from the same supplier. However, small differences 
in the lipid composition (e.g. impurities) might have 
considerable impact on the quality of SLN dispersion (e.g. 
by changing the zeta potential, retarding crystallization 
processes etc).  By increasing the lipid content over 5–10% 
results in larger particles (including micro particles) and 
broader particle size distributions. Both a decrease of the 
homogenization efficiency and an increase in particle 
agglomeration cause this phenomenon which has been 
observed for lipid nanoemulsions, too. 4
CONCLUSION:
The all above formulation methods having many advantages and 
disadvantages but the high drug release is obtained from the high 
pressure homogenization of SLN-NLC type formulation. The non-
uniformity of the SLNs is there in ultra-sonication method.
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